Rock Springs Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Rock Springs Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-368,959	Closed	-$1.93M	–	129
2022 Q2	$1.93M	Hold	368,959	–	–	0.06%	114
2022 Q1	$2.55M	Hold	368,959	–	–	0.06%	123
2021 Q4	$4.59M	Buy	368,959 +6,600	+2%	+$107K	0.11%	118
2021 Q3	$11.3M	Sell	362,359 -20,000	-5%	-$648K	0.24%	102
2021 Q2	$10.9M	Buy	382,359 +4,164	+1%	+$148K	0.22%	108
2021 Q1	$16.4M	Buy	378,195 +17,832	+5%	+$1.18M	0.36%	80
2020 Q4	$25.8M	Buy	360,363 +100	+0%	+$4.97K	0.55%	62
2020 Q3	$10.9M	Buy	+360,263	New	+$10.2M	0.28%	98

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rock Springs Capital Management's PRLD Position: Q3 2022 in Review

Rock Springs Capital Management sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 368,959 shares — an estimated $1.93M sold.

Rock Springs Capital Management first reported a position in PRLD in Q3 2020 and held it in 8 quarters. The position peaked at $25.8M in Q4 2020. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

Rock Springs Capital Management reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
Rock Springs Capital Management sold 368,959 Prelude Therapeutics shares in Q3 2022, an estimated $1.93M.
Rock Springs Capital Management first reported a position in Prelude Therapeutics in Q3 2020 and held it in 8 quarters.
Rock Springs Capital Management's Prelude Therapeutics position peaked at $25.8M in Q4 2020.
53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.